Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OptiNose Inc.

www.optinose.com

Latest From OptiNose Inc.

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Deals Financing

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Immune Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • OptiNose AS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OptiNose Inc.
  • Senior Management
  • Peter K Miller, CEO
    Keith Goldan, CFO
    Per G Djupesland, MD, PhD, CSO
    Ramy A Mahmoud, MD, PhD, Pres. & COO
    John Messina, PharmD, SVP, Clinical Dev.
    Michael Richardson, VP, Bus. Dev.
  • Contact Info
  • OptiNose Inc.
    Phone: (47)(267) 364-3500
    1010 Stony Hill Rd., Ste. 300
    Yardley, PA 19067
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register